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Abstract 
 
Objective: Higher wellbeing is associated with lower levels of inflammatory markers in healthy 
populations; however, it is unclear whether this association translates into a reduced risk of 
disease. In the current study, we tested whether the association between wellbeing and 
inflammation results in a lower risk of arthritis. 
 
Methods: The sample consisted of 5,622 participants aged ≥ 50 from the English Longitudinal 
Study of Ageing and included 6 waves of data collection. We used a structural equation 
modelling approach to test whether inflammatory markers (C-reactive protein or fibrinogen) 
mediated the association between wellbeing and arthritis risk over a 10 year follow up period.  
 
Results: Higher levels of wellbeing were associated with a decrease in arthritis risk (hazard ratio 
= 0.97 per unit; 95% confidence interval = 0.96, 0.98; p < 0.001). Of the two inflammatory 
markers, only C-reactive protein was associated with arthritis risk. Mediation analysis revealed 
that the indirect effect of wellbeing (at wave 1) on arthritis risk via CRP (at wave 2) was 
significant (hazard ratio = 0.996; 95% confidence interval = 0.995, 0.998; p < 0.001). This effect 
remained significant following adjustment for demographic and health behaviour variables and 
depressive symptoms.  
 
Conclusion: C-reactive protein accounts for a small proportion of the association between 
wellbeing and a reduced risk of arthritis. 
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Key Words: Wellbeing, Arthritis, Inflammation, Mediation, Longitudinal Study 
 
Acronyms: ELSA = English Longitudinal Study of Ageing; CASP = control, autonomy, self-
realization and pleasure; CRP = C-reactive protein; CES-D = Center for Epidemiological Studies 
Depression Scale; BMI = body mass index; HR = hazard ratio; CI = confidence interval; SD = 
standard deviation; M = mean; Mdn = median; IQR = interquartile range 
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Introduction 
Following the finding that wellbeing is predictive of health outcomes such as disease risk and 
longevity (1–4), a number of studies have explored the possibility that wellbeing directly affects 
biological processes relevant to disease risk (5). Here, we focus on the link between wellbeing 
and inflammatory processes. Several cross-sectional studies have documented an association 
between high wellbeing or optimism and lower levels of inflammatory markers including 
interleukin (IL)-6, C-reactive protein (CRP) fibrinogen and homocysteine (6–11). These 
associations are not fully accounted for by differences in demographic factors, depressive 
symptoms or health behaviours – suggesting that wellbeing may directly affect inflammatory 
systems, potentially, via prefrontal and limbic system pathways (5).  
 
The link between wellbeing and inflammation may be clinically significant because elevated 
markers of inflammation in older adults are associated with a higher risk of disease and disability 
(12). However, the extent to which the association between wellbeing and inflammatory 
processes accounts for the relationship between wellbeing and disease risk remains to be 
explored. In the current study, we tested whether the association between high wellbeing and 
lower levels of inflammation translates into a reduced risk of one particular disease: arthritis. 
 
We chose to examine the link between wellbeing and risk of arthritis for two reasons. Firstly, 
inflammation is implicated in the aetiology and progression of rheumatoid and osteoarthritis (13–
16). Thus, down regulation of inflammatory processes associated with high wellbeing could 
result in a reduced disease risk. Secondly, in a previous study, we found evidence of an 
association between wellbeing and arthritis risk (17). Using data from the Survey of Health 
AC
CE
PT
ED
 
 
Ageing and Retirement in Europe (SHARE), we found that higher wellbeing was associated with 
a reduced risk of arthritis over a 9 year follow up period. This association remained significant 
although attenuated after adjusting for demographic variables, depressive symptoms, 
comorbidities and health behaviours – suggesting that additional (potentially psychobiological) 
mechanisms underlie the association between wellbeing and arthritis risk. Here we tested this 
hypothesis; specifically, we examined whether the association between wellbeing and arthritis 
risk is partly mediated by the effect of wellbeing on biomarkers of inflammation. 
 
The English Longitudinal Study of Ageing is a representative sample of men and women aged 
50 or older living in England. This dataset includes measures of two inflammatory biomarkers 
which have previously been related to arthritis onset or progression: C-reactive protein (CRP) 
(14,18) and fibrinogen (19). The ELSA dataset also includes a measure of wellbeing (CASP-19). 
Research into the association between wellbeing and health has been informed by three distinct 
measures of wellbeing: evaluative wellbeing (life satisfaction), hedonic wellbeing (feelings of 
joy or happiness) and eudemonic wellbeing (sense of purpose in life) (20). The CASP-19 is 
designed to assess hedonic and eudemonic wellbeing; Higher CASP-19 score have previously 
been associated with lower levels of CRP and fibrinogen in women (9) and an abridged (12 item) 
version of the CASP has been found to predict arthritis risk (17).  
 
Our aim was to test whether levels of CRP or fibrinogen mediated the association between 
wellbeing and incident arthritis. The ELSA dataset currently consists of six waves of data 
collection. We predicted that the association between wellbeing at wave 1 and incident arthritis 
(over the follow up period) would be mediated by biomarker concentrations at wave 2. In 
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addition, we predicted that change in wellbeing over the 6 waves would be associated with 
arthritis risk and that this association would be mediated by change in biomarker levels.  
 
Method 
Study Sample 
ELSA participants are aged ≥50 and were initially recruited from the Health Survey for England 
database in 1998, 1999 and 2001. At wave 1 (2002-3) 11,391 core participants were recruited; 
since then, participants have been interviewed biennially. Refreshment samples drawn from the 
Health Survey for England were added at Wave 3 and 4 to maintain the representation of people 
aged 50-75. Currently, there are 6 waves of data available (from 2002-2012). In addition to the 
main interview, blood samples were taken in waves 2, 4 and 6 during a separate nurse visit. 
Ethical approval for all ELSA waves was provided by the London Multicentre Research and 
Ethics Committee. All participants gave written informed consent (21).  
 
5,622 participants were included in our sample. Participants were excluded if they reported a 
history of arthritis or did not know whether they had been diagnosed with arthritis at wave 1 (n = 
3,721) (we excluded these participants so that the wellbeing measure preceded arthritis 
diagnosis). We also excluded participants if they had missing covariate data at wave 1 (n = 
2,048). See Figure S1 (Supplemental Digital Content 1, http://links.lww.com/PSYMED/A395) 
for a summary of how we derived our sample. See Table S1 for a comparison of covariates 
among included and excluded participants. Compared with excluded participants, participants 
included in our sample were younger, reported fewer depressive symptoms, were wealthier, were 
more likely to be female, had a higher BMI, were more physically active, drank more frequently, 
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were more likely to have a partner, had more years of education, were less likely to report a 
history of diabetes, cardiovascular disease (CVD) and more likely to report a history of 
hypertension. 
 
We did not exclude participants with missing CASP-19 or CRP data. Mplus uses all available 
data to estimate the model using full information maximum likelihood. This approach to 
handling missing data is recommended over listwise deletion, pairwise deletion, and similar 
response pattern imputation (3). 
 
Wellbeing  
Wellbeing was assessed at each wave with the CASP-19 quality of life questionnaire (22). The 
CASP-19 is designed to measure wellbeing across the sub-domains of control, autonomy, self-
realisation and pleasure. Participants respond to 19 questions on a four point Likert scale (scored 
0-3). Possible scores range from 0 to 57 with higher scores indicating higher wellbeing. For the 
study sample, the internal consistency reliability at wave 1 was high (α= 0.86). 
 
Inflammatory biomarkers 
Participants who were not taking anti-coagulant drugs and did not have clotting or bleeding 
disorders were invited to provide a blood sample. Fasting samples (no food or drink except water 
for the past 5 hours) were taken where possible (44% of the blood samples taken at wave 2 were 
fasting samples). Samples were assayed for high-sensitivity CRP and fibrinogen at the Royal 
Victoria Infirmary, Newcastle-upon-Tyne, UK. CRP concentration was measured in 
milligram/litre (mg/l) (normal range is 3 mg/l or less (23)) and fibrinogen was measured in 
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grams (g/l) per litre (normal range 1.45 -3.48 g/l (24)). Due its skewed distribution, we log-
transformed the CRP measure. 
 
Incident Arthritis 
At wave 1, participants were asked whether a doctor had ever told them that they had “arthritis or 
rheumatism”. Participants reported the month and year of their diagnosis. In subsequent waves 
participants were asked to report whether they had been diagnosed with arthritis or rheumatism 
since their last interview. If a new diagnosis was reported, participants reported the month and 
year of diagnosis. 
 
Covariates 
We chose to adjust for factors that could account for the association between wellbeing and 
arthritis risk. These covariates were: Age, sex, depressive symptoms, socio-economic status, 
level of education, relationship status, health behaviours (physical activity, alcohol consumption 
and smoking status) and body mass index (BMI). These factors have previously been linked with 
wellbeing (20,25–28), arthritis risk (29–33) and CRP levels (34–36). We additionally adjusted 
for prevalent hypertension, diabetes and CVD at wave 1 as these conditions commonly co-occur 
with arthritis (37) and have been linked to lower wellbeing (38).  
 
The eight item version of Center for Epidemiological Studies Depression Scale (CES-D) was 
used to assess depressive symptoms (39). Socio-economic status was indexed by total household 
wealth, which has been identified as the most accurate indicator of long-term socio-economic 
circumstances in ELSA (40). Education was categorised based on highest reported level of 
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qualification: less than O-level or equivalent, O-level or equivalent, A-level or equivalent, higher 
than A-level but below degree and degree level (the U.S. equivalent qualifications are the high 
school diploma for O-level and one year of study at college or university with a B average for A-
level). Relationship status was dichotomised as having (coded 1) or not having (coded 0) a 
partner. Participants reported the frequency with which they engaged in vigorous, moderate and 
mild exercise. Response options were „more than once a week‟, „once a week‟, „one to three 
times a month‟ and „hardly ever or never‟. As previously (41), responses to physical activity 
questions were recoded as either once a week (or more) or less than once a week. We then 
created four categories: physical inactivity, mild but not moderate/vigorous activity at least once 
a week, moderate but not vigorous physical activity at least once a week and vigorous physical 
activity at least once a week. Frequency of alcohol consumption was recorded. Response options 
were: twice a day or more, daily or almost daily, once or twice a week, once or twice a month, 
special occasions only and not at all. Participants reported their smoking status as either non-
smoker, ex-smoker or current smoker. BMI was derived from height and weight measures taken 
during the nurse visit at wave 0 which took place between 1998, 1999 and 2001 (there was no 
BMI measure at wave 1). 
 
To summarise, we used wellbeing measures from waves 1- 6, CRP and fibrinogen measures 
from waves 2, 4 and 6, a BMI measure from wave 0 and all other covariate measures from wave 
1. 
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Analysis 
We ran preliminary analysis to establish whether log-CRP or fibrinogen levels at wave 2 were 
associated with arthritis risk in our sample. Each biomarker was entered separately into a Cox 
proportional hazards model which was additionally adjusted for age and sex. Only CRP was a 
significant predictor of arthritis risk (p = 0.001). Consequently, we only tested for mediation 
using CRP.  
 
To examine the association between CASP-19 or CRP with arthritis risk, we ran a Cox 
proportional hazards model predicting arthritis risk that included age, sex and latent variables 
representing wellbeing and CRP initial status (intercepts) at wave 1 and wave 2 respectively, and 
amount of change (slopes) in wellbeing and CRP over the follow up period (42). We used 
unstandardized CRP and wellbeing scores in line with Seltzer, Frank and Bryk‟s (43) 
recommendation. Unstandardized parameter estimates are in the units of the original scale. The 
CASP-19 slopes were defined so that slopes represented the predicted amount of change in 
CASP-19 score every 2 years (between waves). Slopes ranged from -4.65 to 1.86 (M = -0.69, SD 
= 0.57). CRP slopes represented the predicted amount of change in log-CRP concentration every 
4 years (between waves 2, 4 and 6). These slopes ranged from -0.47 to 0.32 (M= -0.03, SD = 
0.05).  
 
We ran mediation analysis testing two possible mediation pathways. Specifically, we tested 
whether the association between wellbeing at wave 1 and arthritis risk was mediated by CRP 
concentrations at wave 2, and, whether the association between change in wellbeing and arthritis 
risk was mediated by change in levels of CRP. Mediation analyses were conducted in Mplus 
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Version 7.4 (44) using a maximum likelihood robust (MLR) estimator and Monte Carlo 
integration. We tested for mediation using a structural equation modelling approach (45). This 
allowed us to estimate the direct effect of CASP-19 (intercept or slope) on arthritis risk and the 
indirect or mediated effect of CASP-19 (intercept or slope) on arthritis risk through CRP 
(intercept or slope). Mplus uses the Delta method (46) to calculate indirect effects and provides 
standard errors, confidence intervals, and significance tests.  
 
We repeated these analysis additionally adjusting for wealth, education, relationship status, 
depressive symptoms, health behaviours, BMI and comorbidities.  
 
In order to test for the effect of reverse causation (specifically, undiagnosed arthritis at baseline 
affecting wellbeing and diagnosis of arthritis pre-dating first CRP measurement), we re-ran the 
analysis excluding participants diagnosed with arthritis at wave 2. 
 
To test whether we would find similar results over a shorter time period; we repeated the analysis 
using only data collected between waves 1 and 4. As there were only two measures of CRP 
within this time period, we could not estimate CRP slope in this analysis. Instead, we created a 
measure of residual change in CRP between waves 2 and 4. This was achieved by regressing 
CRP at wave 4 on CRP at wave 2 with adjustment for follow-up duration, the standardised 
residuals from this analysis were used as the residual change measure (47). We then ran the Cox 
proportional hazards model outlined above replacing CRP slope with the residual change 
measure. The sample size (n = 2,071) for this analysis was smaller as we excluded participants 
with missing CRP (at waves 2 or 4). 
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Coefficients of log-transformed dependent variables were back-transformed using the formula 
(e
β1
-1)*100 and interpreted as the average percentage change in the dependent variable according 
to a unit increase in the independent variable. Log-transformed independent variables were back-
transformed using the formula β1*ln(1.01) and interpreted as the amount of change in the 
dependent variable according to a 1% increase in the independent variable (48). 
 
Results 
There were 1,090 incident cases of arthritis between waves 2 and 6. Table 1 shows the number of 
new diagnoses reported at each wave as well as mean CASP-19 score (at waves 1 to 6) and CRP 
concentration (mg/l) (at waves 2, 4 and 6).  
 
Table 2 shows baseline characteristics of the sample (n = 5,266) according to wellbeing tertile. 
People with high wellbeing tended to be younger, wealthier, have a partner, were more likely to 
be female, more educated, more physically active, consumed more alcohol and had lower 
depressive symptom scores. People with high wellbeing were also less likely to be overweight, 
smoke or report a history of diabetes, hypertension or CVD. 
 
In preliminary Cox models adjusted for age and sex, fibrinogen was not associated with arthritis 
risk (for a unit increase in fibrinogen the hazard ratio (HR) was 1.05; 95% confidence interval 
(CI) = 0.94, 1.16; p = 0.39); however, higher levels of log-CRP were significantly associated 
with increased risk. (HR = 1.14 95% CI = 1.08, 1.23; p < 0.001). Difference in median CRP 
concentration between participants that developed arthritis (Mdn = 2.00 mg/l) and those that did 
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not (Mdn = 1.70 mg/l) was significant (p < 0.001) and similar in magnitude to the differences 
reported by Karlson et al. (13) and Nielen (15). 
 
In the age and sex adjusted model (Figure 1), the path from CASP-19 at wave 1 to  CRP at wave 
2 was significant. A unit increase in CASP-19 score at wave 1 was associated with an average of 
2% (95% CI = 2%, 1%; p < 0.001) decrease in CRP concentration at wave 2. The path from 
CASP-19 slope to CRP slope was also significant with a unit increase in CASP-19 slope 
associated with an average of 6% (95% CI = 9%, 5%; p < 0.001) decrease in CRP slope. CASP-
19 at wave 1 and CRP at wave 2 were significant predictors of arthritis risk. A 1 point increase in 
CASP-19 score was associated with a 3% decrease in arthritis risk (hazard ratio (HR) = 0.97; 
95% CI = 0.96, 0.98; p < 0.001). A 1% increase in CRP concentration at wave 2 was associated 
with an average of  0.002%  (HR = 1.002; 95% CI = 1.001, 0.002; p < 0.001) increase in arthritis 
risk. CASP-19 slope was also a significant predictor of arthritis risk; a unit increase in CASP-19 
slope was associated with a 20% decrease in arthritis risk (HR = 0.80; 95% CI = 0.74, 0.91; p < 
0.001). CRP slope was not a significant predictor of arthritis risk. Mediation analysis revealed 
that the indirect effect of CASP-19 intercept on arthritis risk via CRP intercept was significant 
with 1 unit increase in CASP-19 associated with a 0.004% reduction in arthritis risk (p < 0.001). 
However, the indirect effect of CASP-19 slope via the CRP slope was not significant. The results 
of this model (including fit indices) are displayed in Table S2 (Supplemental Digital Content 1, 
http://links.lww.com/PSYMED/A395). 
 
Estimates in the model that also adjusted for wealth, education, relationship status, depressive 
symptoms, health behaviours, BMI and comorbidities were similar to those in the age and sex 
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adjusted model. However, the association between CRP at wave 2 and arthritis risk, which was 
attenuated (HR = 1.001; 95% CI = 1.000, 1.002; p = 0.016). The association between CASP-19 
slope and arthritis risk was also attenuated (HR: 82; 95% CI = 0.69, 0.96). The indirect effect of 
CASP-19 intercept on arthritis risk via CRP intercept remained significant with a unit increase in 
CASP associated with a 0.002% (p = 0.020) reduction in arthritis risk (see Figure 2). The results 
of this model (including fit indices) are displayed in Table S3 (Supplemental Digital Content 1, 
http://links.lww.com/PSYMED/A395). 
 
Additional factors signficantly associated with a higher arthritis risk in the fully adjusted model, 
included: being female, being diagnosed with hypertension, having a higher depressive symptom 
score and having a higher BMI.   
 
We re-ran the age and sex adjusted model excluding participants diagnosed with arthritis at wave 
2. Results were similar to those in the original analysis; a unit increase in CASP-19 intercept was 
associated with a 2% (p < 0.001) reduction in arthritis risk via the direct pathway and 0.003% 
reduction in arthritis risk via the indirect pathway (via CRP intercept) (p = 0.004). 
 
In analysis using data from waves 1 to 4 only, direct pathways from CASP-19 and CRP 
intercepts to arthritis risk were attenuated but remained significant as did the association between 
CASP-19 and CRP intercept. However, the indirect pathway from CASP-19 intercept (via CRP 
intercept) to arthritis risk was no longer significant (p = 0.057). The indirect pathway from 
CASP-19 slope (via change in CRP) to arthritis risk was also not significant (p = 0.188).  
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Discussion 
High wellbeing is associated with a reduced risk of developing arthritis. Our aim was to test 
whether CRP or fibrinogen mediated this association. Only CRP was associated with arthritis 
risk. Our analysis revealed that the association between wellbeing at wave 1 and arthritis risk 
over a 10-year period was partially mediated by CRP concentration at wave 2. However, it 
should be noted that CRP concentration accounted for only 12% of this risk association. 
Although change in wellbeing over the follow up period was associated with arthritis risk, this 
association was not mediated by change in CRP. 
 
Our estimated effect size for the association between wellbeing and arthritis risk was similar to 
that found in our previous study (17); although, in contrast to this previous study, we did not 
detect a stronger association at younger ages.  
 
The significant pathway between wellbeing at wave 1, CRP concentration at wave 2 and arthritis 
risk suggests that inflammatory processes are implicated in the link between wellbeing and 
arthritis risk. Although this mediation effect was modest, it supports the idea that wellbeing can 
affect disease risk via biological pathways. 
 
Our estimate for the association between wellbeing and CRP is comparable to the association 
reported in a cross-sectional study in which a SD increase in quality of life score was associated 
with a 9.42% reduction in CRP concentration (6). However, as in this cross-sectional study, the 
direction of effect between wellbeing and CRP concentration is unclear. It is possible that 
reduction in CRP is a downstream consequence of high wellbeing on prefrontal and limbic 
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system processes (49). Alternatively, it is also possible that inflammatory processes could affect 
wellbeing as they have been linked to insomnia, fatigue, hostility and depression (50,51). It is 
perhaps most likely that wellbeing and CRP are reciprocally related; additional intervention 
studies could help quantify the extent to which wellbeing can affect CRP concentration or vice 
versa. 
 
The mediation effect in our study was small due to the fact that CRP concentration at wave 2 was 
only weakly related to arthritis risk. Deane et al. (52) suggest that single inflammatory markers 
do not provide a reliable indicator of arthritis risk. This limitation may account for the weak 
association between CRP and arthritis risk as well as the insignificant association between 
fibrinogen and arthritis risk in our sample. A more accurate prediction of risk can be achieved by 
combining measures of multiple arthritis-related biomarkers including levels of autoantibodies 
and cytokines/chemokines (52). A model of the association between wellbeing and arthritis risk 
including these measures may reveal a stronger mediation effect than the one observed here. 
 
We found that wellbeing and CRP slopes were significantly and inversely related - such that an 
increase in wellbeing between waves was associated with a decrease in CRP concentration 
between waves. The significant relationship between wellbeing and CRP trajectories could result 
from mechanisms similar to those outlined earlier. That is, change in wellbeing could cause a 
change in CRP concentration via psychobiological pathways, or, change in physical symptoms 
(for instance, chronic pain or disability) associated with levels of inflammation could affect an 
individual‟s sense of wellbeing. 
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Change in wellbeing was associated with arthritis risk; however, change in CRP did not mediate 
this association. This is because change in CRP was not related to arthritis risk. Further work is 
needed to establish the timing between change in CRP concentration and the onset of arthritic 
symptoms (53). However, there is some indication that elevation in CRP concentration can 
precede the onset of symptoms by up to 20 years (14). It is possible that the 8 year follow-up 
period (waves 2-6) in our study was too short to capture changes in CRP concentration relevant 
to arthritis risk. In addition, participants that left the study before wave 6 had significantly higher 
levels of CRP at wave 2 than participants that remained in the study. This pattern of attrition 
could have resulted in an underestimation of the association between CRP or CRP change and 
arthritis risk in our study as participants that left may have had a higher risk of arthritis.  
 
Analysis excluding participants diagnosed with arthritis at wave 2 yielded similar results – 
indicating that our findings are unlikely to reflect the effect of reverse causation. That is, 
undiagnosed arthritis affecting reports of wellbeing at wave 1. Results from analysis using a 
shorter follow up-period (4 years) were less consistent with our original findings. The indirect 
effect of wellbeing intercept (via CRP at wave 2) on arthritis risk was no longer significant. It is 
possible that this insignificant result was due to the lower power of this analysis (the number of 
incident cases was 421 compared with 1,090 in our original analysis). 
 
Our findings should be interpreted with caution as this study had some important limitations. 
Excluding a significant proportion of participants from our sample (due to missing data at wave 
1) may have introduced a source of selection bias. Participants excluded from our sample 
differed to those included on a number of covariate variables (see Table S1, Supplemental 
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Digital Content 1, http://links.lww.com/PSYMED/A395). In addition, arthritis incidence was 
ascertained using self-report. Although access to medical records would have been preferable, 
there is evidence that self-report of arthritis diagnosis is consistent with clinically derived 
measures (54). Finally, we were unable to distinguish between cases of rheumatoid arthritis and 
osteoarthritis. It is likely that the mechanisms underlying the association between wellbeing and 
rheumatoid or osteoarthritis are qualitatively different because these conditions involve distinct 
pathophysiological processes. Our study also had several strengths. The sample size was large 
and we were able to control for many possible confounds.  
 
In summary, our results indicate that CRP concentration mediates the association between 
wellbeing and arthritis risk (after taking demographic and health behaviour differences into 
account). Although the magnitude of this mediating effect was small, we believe our findings 
have theoretical implications. Specifically, they provide a proof of principle that biological 
processes can partially mediate the link between wellbeing and disease. CRP concentration 
represents a small component of a dynamic and interactive biological system. A combination of 
multiple measures of biological function would enable researchers to assess the clinical 
significance of the pathway between wellbeing, psychobiological processes and disease risk (55). 
We hope that our findings will help motivate this line of investigation. 
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Figure Captions 
 
Figure 1. Path model adjusted for age and sex. Numbers in parentheses are exponentiated path 
coefficients (HRs). 
a
 Coefficients have been transformed to represent percentage change in CRP intercept or slope 
according to a unit increase in CASP intercept or slope. 
b
 Coefficients have been transformed to represent increase in arthritis risk according to a 1% 
increase in CRP intercept or slope. 
* * = p < 0.001, * = p < 0.05, ns = p ≥ 0.05 
 
Figure 2. Path model additionally adjusted for comorbidities, demographic and health behavior 
variables. Numbers in parentheses are exponentiated path coefficients (HRs). 
a
 Coefficients have been transformed to represent percentage change in CRP intercept or slope 
according to a unit increase in CASP intercept or slope. 
b
 Coefficients have been transformed to represent increase in arthritis risk according to a 1% 
increase in CRP intercept or slope. 
* * = p < 0.001, * = p < 0.05, ns = p ≥ 0.05 
 
 
  AC
CE
PT
ED
 
 
Figure 1 
 
 
  
AC
CE
PT
ED
 
 
Figure 2 
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Table 1.  Incident Cases of Arthritis, Mean CASP-19 score and Median CRP concentration at 
each wave 
Measure T1 T2 T3 T4 T5 T6 
Incident Cases of 
Arthritis 
 367 231 198 159 135 
CASP-19 M (SD) 63.39 
(7.77) 
63.21 
(8.03) 
61.58 
(8.01) 
61.32 
(8.17) 
61.38 
(8.33) 
61.17 
(8.08) 
CRP mg/l Mdn 
(IQR)  
 1.80 (0.90-
3.80) 
 1.80 (0.90-
3.80) 
 1.60 (0.80-
3.20) 
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Table 2. Baseline characteristics stratified according to tertiles of CASP-19 scores (lowest, 
middle and highest subjective wellbeing) 
Characteristics Lowest Middle Highest  p-trend
a 
N 1577 1425 1616  
Age (yrs), M (SD) 63.28 (9.90) 62.67 (9.15) 61.69 (8.47) <0.001 
Wealth, M (SD) (in £100,000) 1.95 (4.65) 2.41 (3.11) 3.30 (5.62) <0.001 
BMI (kg/m
2)
, M (SD) 27.23 (4.46) 27.14 (4.10) 26.94 (4.07) 0.054 
CESD Score ≥ 4, No. (%)  228 (14) 56 (4) 11 (1) <0.001 
Female, No. (%) 351 (54) 735 (47) 855 (52) <0.001 
Physical Activity, No. (%)    <0.001 
   Inactive 140 (9) 56 (4) 48 (3)  
   Mild  229 (14) 128 (9) 92 (6)  
   Moderate  816 (52) 716 (50) 785 (47)  
   Vigorous  392 (25) 525 (37) 691 (43)  
Alcohol, No. (%)    <0.001 
   At least twice a day 58 (4) 70 (5) 82 (5)  
   Daily or almost daily 375 (24) 378 (27) 490 (30)  
   Once or twice a week 507 (32) 505 (35) 564 (35)  
   Once or twice a month 172 (11) 150 (11) 180 (11)  
   Special occasions only 321 (20) 224 (16) 199 (12)  
   Not at all 144 (9) 98 (7) 101 (6)  
Smoking, No. (%)    <0.001 
   Smoker 353 (22) 220 (15) 222 (14)  
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   Former smoker 705 (45) 661 (46) 736 (46)  
   Non smoker  519 (33) 544 (38) 658 (41)  
No partner, No. (%) 496 (31) 303 (21) 348 (22) <0.001 
Education, No. (%)    <0.001 
   Less than O-level 840 (53) 646 (45) 648 (40)  
   O-level  281 (18) 283 (20) 307 (19)  
   A-level  108 (7) 99 (7) 118 (7)  
   Higher education  173 (11) 187 (13) 250 (16)  
   Degree level  175 (11) 210 (15) 293 (18)  
Diabetes, No. (%) 129 (8) 75 (5) 64 (3) <0.001 
CVD No. (%) 160 (10) 87 (6) 72 (4) <0.001 
Hypertension, No. (%) 578 (36) 489 (34) 473 (29) <0.001 
a
 Statistical significance is based on χ2 tests or one-way ANOVA, as appropriate. 
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